Startseite Adjuvant activity of type I interferons
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Adjuvant activity of type I interferons

  • Michael G. Tovey , Christophe Lallemand und George Thyphronitis
Veröffentlicht/Copyright: 27. März 2008
Biological Chemistry
Aus der Zeitschrift Band 389 Heft 5

Abstract

Type I interferons (IFNs) produced primarily by plasmacytoid dendritic cells (pDCs) as part of the innate immune response to infectious agents induce the maturation of myeloid DCs and enhance antigen presentation. Type I IFNs also enhance apoptosis of virus-infected cells, stimulate cross priming and enhanced presentation of viral peptides. Type I IFNs are powerful polyclonal B-cell activators that induce a strong primary humoral immune response characterized by isotype switching and protection against virus challenge. Type I IFNs stimulate an IgG2a antibody response characteristic of Th1 immunity when ad-mixed with influenza virus vaccine and injected intramuscurarly (i.m.) or administered intranasally. The adjuvant activity of type I IFNs has been shown to involve direct effects of IFN on B-cells, effects on T-cells, as well as effects on antigen presentation. Oromucosal administration of type I IFNs concomitantly with i.m. injection of vaccine alone can also enhance the antibody response to influenza vaccination by enhancing trafficking of antigen-presenting cells towards the site of vaccination. Recombinant IFNs are potent adjuvants that may find application in both parenterally and mucosally administered vaccines.


Corresponding author

Published Online: 2008-03-27
Published in Print: 2008-05-01

©2008 by Walter de Gruyter Berlin New York

Artikel in diesem Heft

  1. Guest Editorial
  2. Novel paradigms in vaccine development: from small pox eradication to therapeutic vaccines
  3. Highlight: 3rd Semmering Conference 2007
  4. Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine
  5. Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors
  6. Novel strategies to identify biomarkers in tuberculosis
  7. Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection
  8. Lipopolysaccharide: a tool and target in enterobacterial vaccine development
  9. The coming of age of virus-like particle vaccines
  10. Maintenance of serological memory
  11. Adjuvant activity of type I interferons
  12. Japanese encephalitis vaccines – needs, flaws and achievements
  13. Analysis of the human cytomegalovirus pp65-directed T-cell response in healthy HLA-A2-positive individuals
  14. Non-regulatory CD8+CD45RO+CD25+ T-lymphocytes may compensate for the loss of antigen-inexperienced CD8+CD45RA+ T-cells in old age
  15. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines
  16. Construction of an encapsulated ESAT-6-based anti-TB DNA vaccine and evaluation of its immunogenic properties
  17. Review
  18. RNA switches regulate initiation of translation in bacteria
  19. Protein Structure and Function
  20. Inhibition of bacterial oxidases by formamide and analogs
  21. Modeling of variant copies of subunit D1 in the structure of photosystem II from Thermosynechococcus elongatus
Heruntergeladen am 11.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/BC.2008.051/html
Button zum nach oben scrollen